GlobalData on MSN

Revolution’s RAS inhibitor pipeline posts more pancreatic cancer trial wins

The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic ...

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...
News Medical

An Overview of RAS Oncoproteins

RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in 2016 ...